ZEO ScientifiX
- Company typePublic
- Founded2024
- HeadquartersFort Lauderdale, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
ZEO ScientifiX firmographics
Firmographics- Name
- ZEO ScientifiX
- Legal name
- ZEO ScientifiX, Inc.
- Website
- https://zeoscientifix.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ZEO ScientifiX industry classification
Industry- Product category
- Regenerative Biologics Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where ZEO ScientifiX is headquartered
LocationHeadquarters
- HQ city
- Fort Lauderdale
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
ZEO ScientifiX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Biologic Product Sales: Sale of regenerative biologics including stem cells, extracellular vesicles, Wharton's Jelly matrix, amniotic membrane patches, and autologous EV concentrates to physicians and healthcare providers for clinical use in regenerative medicine treatments.
- Masterclass Education Programs: Physician education and training programs including monthly Masterclasses at Nova Southeastern University ($200 per attendee) and virtual webinars. Expanded to patient-facing Masterclass programs hosted by physician partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | On-site Physician Masterclass |
| Freemium | Pay-as-you-go | Virtual Webinar |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels12 records
ZEO ScientifiX product offering
Product offeringCore offering
ZEO ScientifiX manufactures and sells regenerative biologic products—including umbilical cord-derived stem cells (DayZero™), Wharton's Jelly-derived extracellular vesicles, amniotic membrane patches, and an autologous platelet-derived EV system (PPX™)—to physicians and healthcare providers for use in orthopedics, wound care, pain management, and longevity therapies. The company also operates physician education Masterclass programs at Nova Southeastern University.
Product overview
ZEO ScientifiX is a clinical-stage biotechnology company specializing in the development and controlled production of biologic materials for investigational, research, and regulated clinical applications. The company operates within established quality systems and regulatory frameworks, supporting scientific collaboration with healthcare professionals and institutions. Their product portfolio centers on regenerative biologics including the DayZero™ line of products derived from perinatal sources (umbilical cord stem cells and Wharton's Jelly Matrix), amniotic membrane patches, and the Patient Pure X™ (PPX™) autologous system. DayZero™ biologics are collected within hours of delivery, screened, documented, processed in an FDA-registered cGMP facility, and cryopreserved to preserve potency. The company also offers physician education through Masterclass programs and maintains a provider directory connecting physicians with their biologic products.
Differentiator
Problem solved
Functional benefit
Brands
- DayZero: Product line including DayZero Stem Cells and DayZero EV products derived from perinatal sources, including umbilical cord stem cells, Wharton's Jelly Matrix, and amniotic membrane patches.
- Patient Pure X (PPX)
Products and services
- DayZero™ Stem Cells Umbilical cord-derived allogeneic stem cells offered to physicians in vial and IV bag formats for use in orthopedics, pain management, and advanced wound care. Cells are ethically sourced, screened, and processed in an FDA-registered cGMP facility.
- DayZero™ EV (Wharton's Jelly Matrix) Gelatinous scaffold combining natural collagen and hyaluronic-rich matrix with a dense extracellular vesicle payload, offered to physicians in 50B, 100B, and 200B EV vial sizes for regenerative procedures.
- Amniotic-Membrane Patches Biological extracellular membrane sheets that retain endogenous growth factors and an intact collagen network, used by physicians as a dressing for surgical closure and chronic wound treatment.
- Patient Pure X™ (PPX™) Autologous extracellular vesicle system in which the patient's own platelets are collected chair-side and processed in an FDA-registered cGMP facility using a proprietary centrifugation sequence to concentrate platelet-derived EVs; offered to physicians in 100B, 200B, and 400B vial sizes.
- Physician Masterclass Program Paid educational and training program for physicians on regenerative medicine compliance, clinical applications, and product use, delivered monthly at Nova Southeastern University ($200 per attendee) and via free virtual Zoom webinars.
Quantifiable outcome
- Over 500 physicians trained in regenerative medicine compliance through monthly Masterclass programs
- +3 more outcomes
Companies that use ZEO ScientifiX
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
ZEO ScientifiX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ZEO ScientifiX partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, minor and major.
- Regen TherapycoreMOU for exclusive scientific and biologics strategic collaboration positioning ZEO as the core supplier of advanced biologic therapeutics for Regen Therapy's platform of 3,000+ clinics and 24,000 practitioners. Creates vertically integrated ecosystem combining clinical delivery, telemedicine infrastructure, and biologic product development for regenerative and longevity care at scale.
- Stealth HealthcoreStrategic partnership with Stealth Health to deploy white-label telemedicine and longevity services across Regen Therapy's clinical network. Enables clinics to offer physician-guided consultations, hormone replacement therapy, GLP-1 weight management programs, and data-driven longevity protocols.
- American Academy of Anti-Aging Medicine (A4M)coreOfficial Regenerative Medicine Educational Partner for A4M's Longevity SpringFest 2026 and ongoing programming. ZEO serves as the 'official arm of education' for regenerative medicine, leading specialized full-day Masterclass and gaining direct access to A4M's network of 26,000 physicians and practitioners across 120 nations.
- Cytora TherapeuticscoreThree-way strategic partnership to manufacture and commercialize Cytora's allogeneic human oral mucosal stem cell therapy (CytoraStem™) in the U.S. ZEO handles exclusive U.S. commercialization, initially leveraging Florida's SB 1768 for wound care indications while pursuing FDA Phase 2b clinical trials for diabetic foot ulcers.
- Made ScientificcoreExclusive U.S. GMP manufacturing partner from Princeton, New Jersey facility for Cytora's allogeneic stem cell therapy. Collaboration involves manufacturing, clinical trials, and market access for diabetic foot ulcer treatment.
- ExotropinminorJoint venture to launch solution addressing hair loss unmet need. Combines ZEO's biologic products with Exotropin's expertise.
- Physicians Group, LLCmajorPartnership with multi-state healthcare provider operating 75 clinics with over 750 clinical personnel treating 1,500-2,000 patients monthly. Aims to advance ZEO's clinical trial programs including Phase 2 trials for flagship product Zofin™, leveraging Physicians Group's network and diverse patient population for musculoskeletal and other health indications.
- Nova Southeastern UniversitycoreOperating out of Nova Southeastern University's Center of Collaborative Research, a $100 Million research facility. Hosts monthly Masterclass training programs at Alvin Sherman Library location.
- BioViva ScienceminorListed as strategic partner on website. Founder Elizabeth Parrish serves on ZEO's Medical Advisory Board and is collaborating on XPRIZE Healthspan competition team.
- Minovia TherapeuticsminorListed as strategic partner on website.
- Baptist Health South FloridaminorListed as strategic partner on website. Dr. Michael Swartzon from Baptist Health serves on Medical Advisory Board.
- Hospital for Special Surgery (HSS)minorListed as strategic partner. Dr. Bryan T. Kelly (President & CEO, Surgeon-in-Chief Emeritus) and Dr. Riley J. Williams III serve on Medical Advisory Board.
- NYU Langone HealthminorListed as strategic partner. Dr. Laith M. Jazrawi (Chief, Division of Sports Medicine) serves on Medical Advisory Board.
- Mount Sinai Medical CenterminorListed as strategic partner on website.
- Fountain LifeminorListed as strategic partner. Dr. George C. Shapiro was co-founder and Chief Medical Innovation Officer of Fountain Life.
Scale indicators16 records
Recent moves8 records
Expansion highlights7 records
ZEO ScientifiX competitors and assessment
Company assessmentBroad incumbents
- Mesoblast: Commercial-stage cell therapy company developing mesenchymal stem cell-based treatments for inflammatory and age-related diseases. Comparable in biologic/cellular therapy category and musculoskeletal/regenerative indications, but at much later stage and broader scale.
- Pluristem Therapeutics: Develops placenta-derived allogeneic cell therapies for musculoskeletal, wound healing, and regenerative indications. Highly comparable in source material (perinatal), manufacturing approach (cGMP biologics), and clinical indications.
- AgeX Therapeutics: Clinical-stage biotechnology company focused on regenerative medicine and aging-related cellular therapies. Comparable in therapeutic focus on biological mechanisms of aging and use of stem cell-derived platforms, though larger and more capital-intensive.
Others
- Fountain Life: Longevity and preventive health platform founded/co-founded by ZEO's CMO Dr. George C. Shapiro. Closely aligned in longevity and regenerative medicine patient positioning, providing both customer overlap and brand adjacency.
- Regen Therapy: Clinical delivery and telemedicine platform operating 3,000+ clinics and 24,000 practitioners. ZEO's exclusive biologics distribution partner, making it the dominant channel through which ZEO products reach end providers.
Direct peers
- Kimera Labs: Specializes in perinatal-derived exosome and stem cell products (including Wharton's Jelly-derived EVs) sold to physicians for regenerative applications. Nearly identical upstream sourcing and downstream distribution model to ZEO's DayZero line.
- Direct Biologics: U.S.-based regenerative medicine company developing exosome and stem cell biologic products sold through physicians. Closely comparable product portfolio (EV/exosome therapeutics), physician-channel GTM, and regulatory positioning to ZEO.
Emerging players
- Minovia Therapeutics: Clinical-stage company developing mitochondrial cell therapies for age-related and rare diseases. Listed ZEO strategic partner with overlapping regenerative medicine and longevity thesis, though differentiated by mitochondrial augmentation.
- BioViva Science: Longevity-focused biotech developing gene and cell therapies to address biological aging. ZEO strategic partner and XPRIZE Healthspan collaborator with strongly overlapping aging/longevity therapeutic ambitions.
- Cytora Therapeutics: Developer of allogeneic oral mucosal stem cell therapy (CytoraStem) for diabetic foot ulcers. ZEO's strategic partner for U.S. commercialization and Phase 2b trials; directly comparable in regenerative medicine and wound care focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ZEO ScientifiX social profiles
Digital presenceZEO ScientifiX compliance and trust
Trust signalCompliance3 records
ZEO ScientifiX financial estimates
Financial estimateRevenue estimate
Valuation estimate
ZEO ScientifiX leadership team
Management profileNumber of profiles
Profiles10 records
ZEO ScientifiX funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ZEO ScientifiX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ZEO ScientifiX
What does ZEO ScientifiX do?
ZEO ScientifiX manufactures and sells regenerative biologic products—including umbilical cord-derived stem cells (DayZero™), Wharton's Jelly-derived extracellular vesicles, amniotic membrane patches, and an autologous platelet-derived EV system (PPX™)—to physicians and healthcare providers for use in orthopedics, wound care, pain management, and longevity therapies. The company also operates physician education Masterclass programs at Nova Southeastern University.
Is ZEO ScientifiX a public or private company?
ZEO ScientifiX is a public company. It is classified as public and is currently operating.
When was ZEO ScientifiX founded?
ZEO ScientifiX was founded in 2024. It employs 11 to 50 people.
Where is ZEO ScientifiX based?
ZEO ScientifiX is headquartered in Fort Lauderdale, United States, in the North America region.
How does ZEO ScientifiX make money?
Two revenue lines are on record. Biologic Product Sales are the primary driver. The others are masterclass Education Programs.
Who are ZEO ScientifiX's main competitors?
Broad incumbents on record are Mesoblast, Pluristem Therapeutics and AgeX Therapeutics. Others are Fountain Life and Regen Therapy. Direct peers are Kimera Labs and Direct Biologics. Emerging players are Minovia Therapeutics, BioViva Science and Cytora Therapeutics.
Does ZEO ScientifiX have an API?
No public API is recorded for ZEO ScientifiX.
What industry is ZEO ScientifiX in?
ZEO ScientifiX's product category is Regenerative Biologics Manufacturing. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.